It is very uncertain whether bisphosphonates changes adverse events: osteonecrosis of the jaw compared with placebo/no treatment (very low certainty).
Bisphosphonates probably leads to lower proportion of participants with disease progression compared with placebo/no treatment (moderate certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Laparaoscopic radical prostatectomy and robotic‐assisted… showed no clear difference in overall surgical complications (short‐term) compared with open radical prostatectomy (low certainty).
Potassium citrate may leads to lower proportion of participants who developed a new urinary stone compared with no intervention (low certainty).
It is very uncertain whether potassium citrate changes proportion of participants with adverse events while undergoing… compared with no intervention (very low certainty).
The review found no eligible studies for this question.
Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).
Interferon‐α combined with targeted therapies may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapy (low certainty).
Interferon‐α alone showed no clear difference in 1‐year mortality compared with interferon‐α plus bevacizumab (low certainty).
The review found no eligible studies for this question.
Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).
Interferon‐α plus bevacizumab showed no clear difference in 1‐year mortality median compared with standard targeted therapies (low certainty).
The review found no eligible studies for this question.
Interferon‐α plus bevacizumab showed no clear difference in adverse events (grade ≥ 3) compared with standard targeted therapies (low certainty).
Vaccine treatment showed no clear difference in 1‐year mortality compared with standard therapies (low certainty).